Alimera Sciences (ALIM) to Release Quarterly Earnings on Monday

Alimera Sciences (NASDAQ:ALIM – Get Rating) is scheduled to announce its earnings results before the market opens on Monday, May 9th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Alimera Sciences (NASDAQ:ALIM – Get Rating) last released its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.21). The company had revenue of $13.96 million during the quarter, compared to analysts’ expectations of $14.00 million. During the same period last year, the firm posted ($0.18) earnings per share.

NASDAQ ALIM opened at $5.45 on Friday. Alimera Sciences has a fifty-two week low of $3.94 and a fifty-two week high of $10.50. The stock’s 50-day moving average is $5.55 and its two-hundred day moving average is $5.10. The firm has a market cap of $38.10 million, a P/E ratio of -6.90 and a beta of 1.48.

In other news, major shareholder Stanley Morgan sold 250,000 shares of Alimera Sciences stock in a transaction dated Tuesday, February 8th. The stock was sold at an average price of $4.55, for a total value of $1,137,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 13.50% of the company’s stock.

An institutional investor recently bought a new position in Alimera Sciences stock. Millennium Management LLC bought a new position in shares of Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,716 shares of the biopharmaceutical company’s stock, valued at approximately $65,000. Millennium Management LLC owned approximately 0.18% of Alimera Sciences as of its most recent SEC filing. 40.97% of the stock is owned by institutional investors.

ALIM has been the topic of several recent research reports. Alliance Global Partners cut their target price on Alimera Sciences from $14.50 to $11.00 in a report on Friday, February 25th. HC Wainwright cut their target price on Alimera Sciences from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 25th. Zacks Investment Research upgraded Alimera Sciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, StockNews.com initiated coverage on Alimera Sciences in a research note on Thursday. They issued a “hold” rating on the stock.

Alimera Sciences Company Profile (Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

See Also